Participant flow

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) · Source last updated 2026-07-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

   id

   FG000

   title

   Part 1: Cohort A: METex14 Skipping Alterations

2. description

   Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

   id

   FG001

   title

   Part 1: Cohort B: MET Amplification

3. description

   Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

   id

   FG002

   title

   Part 2: Cohort C: Confirmatory Part for METex14 Skipping Alterations

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         15

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         33

      type

      still on treatment

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         152

      2. group Id

         FG001

         num Subjects

         24

      3. group Id

         FG002

         num Subjects

         161

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         137

      2. group Id

         FG001

         num Subjects

         23

      3. group Id

         FG002

         num Subjects

         128

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         15

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         33

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

For Cohort A: A total of 168 participants were screened of which 152 participants were enrolled to receive the study drug. For Cohort B: A total of 32 participants were screened of which 24 participants were enrolled to receive the study drug. For Cohort C: A total of 175 participants were screened of which 161 participants were enrolled to receive the study drug.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice